Arrhythmias Clinical Trials

• IC 1 Male or female ≥ 18 years

• IC 2 Patients with a clinical indication for catheter ablation due to ischemic and/or non-ischemic heart disease and recurrent symptomatic sustained scar-mediated monomorphic Ventricular Tachycardia.

• IC 3 Any of the following:

‣ Ischemic cardiomyopapthy (ICM) patients with prior history of myocardial infarction with Q waves, focal wall motion abnormality on imaging, fixed perfusion defect correlating with coronary stenosis or prior coronary intervention, 20% ≤ LVEF \< 50%.

⁃ non-ischemic cardiomyopathy (NICM) patients with scar in a territory without coronary stenosis as evidenced by CMR imaging within the prior 90 days or intra-procedurally using EAM and PES prior to investigational device use, 20% ≤ LVEF \< 50%

⁃ Arrhythmogenic right ventricular cardiomyopathy (ARVC)

• IC 4 Has received a market-released ICD prior to enrollment

• IC 5 Patient has had at least 1 documented spontaneous episode of SMVT within the previous 6 months

• IC 6 Refractory to, or intolerant of, at least one Class III AAD. (Refractory or intolerant defined as AAD failure due to recurrent VT, not tolerated/ desired due to side effects)

• IC 7 Willingness, ability, and commitment to participate in baseline and follow-up evaluations for the full length of the study

• IC 8 Willingness and ability to give an informed consent